Davunetide vs Selank

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Selank is believed to modulate the expression of GABA-A receptor subunits and increase BDNF levels, contributing to its anxiolytic and neuroprotective profile. It appears to regulate serotonin transporter gene expression and influence dopaminergic signalling. Unlike classical anxiolytics, it does not appear to produce tolerance or physical dependence in animal models.

Selank (TKPRPGP) is a synthetic heptapeptide anxiolytic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences from a tuftsin-based sequence, incorporating the Thr-Lys-Pro-Arg tuftsin core with a Pro-Gly-Pro C-terminal extension to enhance stability and CNS penetration, and registered in Russia as a pharmaceutical for the treatment of generalized anxiety disorder and adjustment disorders. Selank is proposed to modulate GABAergic, serotonergic, and enkephalinergic neurotransmission and to influence BDNF expression and immune-neurological signaling; intranasal administration is the primary route used clinically, producing rapid CNS delivery with a reportedly favorable tolerability profile based on Russian clinical experience. Human clinical studies published in the peer-reviewed Russian journal Zh Nevrol Psikhiatr Im S.S. Korsakova have examined selank in generalized anxiety disorder and adjustment disorders, reporting anxiolytic efficacy and good tolerability; these studies are indexed in PubMed, though no independently conducted blinded Western randomized controlled trials or external replications exist. Selank is registered as a pharmaceutical drug in Russia and is in active clinical use there; it has no FDA approval and is not approved in any Western jurisdiction, and while the Russian clinical evidence is genuine peer-reviewed work, it has not been validated by the independent replication standards applied to Western regulatory submissions. Intranasal administration — nasal spray — is the primary delivery route in Russian clinical practice, used in the registered pharmaceutical context for generalized anxiety disorder and adjustment disorders. Nasal spray formulations allow for rapid mucosal absorption and CNS penetration without systemic injection. Selank nasal spray is the most common research form used internationally; subcutaneous injection is also studied. Selank peptide dosing has been evaluated in the published Russian clinical literature in the context of anxiolytic and neurological applications; the registered pharmaceutical form specifies intranasal delivery. Selank peptide dosage and dosage chart The registered Russian pharmaceutical form of Selank specifies an intranasal spray concentration of 0.15% (1.5mg/mL). At this concentration, typical protocol doses in the clinical and research literature run 250–750mcg per administration, administered 2–3 times daily — equating to approximately 2–5 drops of 0.15% solution per nostril per dose. A common research protocol reference is 300mcg intranasally (approximately 3 drops of 0.15% solution), 2–3 times daily, for cycles of 10–14 days. Injectable protocols (subcutaneous or intramuscular) used in research contexts reference 250–500mcg once or twice daily; the injectable route has a different pharmacokinetic profile than intranasal and is used less commonly in the existing clinical literature. Higher doses have been studied in Russian clinical settings for more severe anxiety presentations; lower doses (100–250mcg) are often used in research contexts where anxiolytic and nootropic effects are being evaluated together. No approved dosing exists in Western jurisdictions; these figures represent the range documented in Russian pharmaceutical and research literature. Selank and semax together Selank and semax are often discussed as a complementary pairing in the nootropic and research community due to their differing CNS profiles. Semax is a stimulating nootropic — it upregulates BDNF, increases dopamine and serotonin activity, and enhances alertness and cognitive drive. Selank is anxiolytic and calming — it modulates GABAergic tone, reduces anxiety-related arousal, and may counterbalance semax's stimulating effects in individuals prone to stimulant-related anxiety. The combination is proposed to provide cognitive enhancement (via semax) with reduced anxiety burden (via selank), though no controlled clinical trial has evaluated the combination specifically. Both are administered intranasally in clinical and research contexts; the two are sometimes used in separate intranasal preparations on alternating cycles or combined in the same protocol period depending on the individual response profile.